CHRONIC COMPLICATIONS OF DIABETESDVORNIK D.1978; ANNU. REP. MEDICIN. CHEM.; USA; DA. 1978; VOL. 13; PP. 159-166; BIBL. 2 P.Article

COMBINED EFFECTS OF CLOFIBRATE AND DIOSGENIN ON CHOLESTEROL METABOLISM IN RATS.CAYEN MN; DVORNIK D.1978; ATHEROSCLEROSIS; NLD; DA. 1978; VOL. 29; NO 3; PP. 317-327; BIBL. 1 P. 1/2Article

INHIBITION OF TESTOSTERONE BIOSYNTHESIS BY MEDROGESTONEGIVNER MI; DVORNIK D.1972; EXPERIENTIA; SUISSE; DA. 1972; VOL. 28; NO 9; PP. 1105-1106; ABS. FR.; BIBL. 13REF.Serial Issue

THE EFFECT OF PGE₁ ON ADP-INDUCED AGGREGATION IN REFRACTORY PLATELETSSIMARD DUQUESNE N; DVORNIK D.1973; PROSTAGLANDINS; U.S.A.; DA. 1973; VOL. 3; NO 4; PP. 457-460; BIBL. 6REF.Article

HYPOLIPIDEMIC ACTIVITY OF 2,8-DIBENZYL-CYCLOOCTANONE IN RATSCAYEN MN; DUBUC J; DVORNIK D et al.1976; BIOCHEM. PHARMACOL.; G.B.; DA. 1976; VOL. 25; NO 13; PP. 1537-1541; BIBL. 12 REF.Article

CLOFIBRATE AND CLOFIBRIC ACID: COMPARISON OF THE METABOLIC DISPOSITION IN RATS AND DOGS.CAYEN NM; FERDINANDI ES; GRESELIN E et al.1977; J. PHARMACOL. EXPER. THERAPEUT.; U.S.A.; DA. 1977; VOL. 200; NO 1; PP. 33-43; BIBL. 26 REF.Article

Etodolac: effect on prostaglandin concentrations in gastric mucosa of ratsLEE, D; DVORNIK, D.Life sciences (1973). 1985, Vol 36, Num 12, pp 1157-1162, issn 0024-3205Article

PHARMACOKINETICS AND HYPOLIPIDEMIC ACTIVITY OF CLOFIBRATE-NICOTINIC ACID COMBINATIONS IN RATSCAYEN MN; ROBINSON WT; DUBUC J et al.1979; BIOCHEM. PHARMACOL.; GBR; DA. 1979; VOL. 28; NO 7; PP. 1163-1167; BIBL. 24 REF.Article

PRODOLIC ACID. ANALYSIS AND DISPOSITION STUDIES IN RATS AND DOGS.ROBINSON WT; KRAML M; GRESELIN E et al.1977; XENOBIOTICA; G.B.; DA. 1977; VOL. 7; NO 6; PP. 329-337; BIBL. 4 REF.Article

Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestatKEMPER, C; DVORNIK, D.Proceedings of the Society for Experimental Biology and Medicine. 1986, Vol 182, Num 4, pp 505-510, issn 0037-9727Article

BIOPHARMACEUTICAL CHARACTERISTICS OF A NEW PROPRANOLOL/HYDROCHLOROTHIAZIDE TABLET COMBINATIONKRAML M; DUBUC J; DVORNIK D et al.1982; BIOPHARM. DRUG DISPOS.; ISSN 0142-2782; GBR; DA. 1982; VOL. 3; NO 1; PP. 55-65; BIBL. 23 REF.Article

BUTRIPTYLINE: HUMAN PHARMACOKINETICS AND COMPARATIVE BIOAVAILABILITY OF CONVENTIONAL AND SUSTAINED RELEASE FORMULATIONSBOURGOUIN J; GAGNON MA; ELIE R et al.1981; BIOPHARM. DRUG DISPOS.; ISSN 0142-2782; GBR; DA. 1981; VOL. 2; NO 2; PP. 123-130; BIBL. 20 REF.Article

Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestatSIMARD-DUQUESNE, N; GRESELIN, E; GONZALEZ, R et al.Proceedings of the Society for Experimental Biology and Medicine. 1985, Vol 178, Num 4, pp 599-605, issn 0037-9727Article

The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic ratsSIMARD-DUQUESNE, N; GRESELIN, E; DUBUC, J et al.Metabolism, clinical and experimental. 1985, Vol 34, Num 10, pp 885-892, issn 0026-0495Article

Tolrestat pharmacokinetics in rat peripheral nerveDVORNIK, D; MILLEN, J; HICKS, D. R et al.Journal of diabetes and its complications. 1994, Vol 8, Num 1, pp 18-26, issn 1056-8727Article

Relationship between plasma propranolol concentration and dose in young, healthy volunteersDEY, M; BRISSON, J; DAVIS, G et al.Biopharmaceutics & drug disposition. 1986, Vol 7, Num 2, pp 103-111, issn 0142-2782Article

Dose proportionality comparison of beta₁ blocking activity of cetamolol hydrochloride and atenolol in normal subjectsKLAUSNER, M. A; COELHO, J. B; DVORNIK, D et al.Current therapeutic research. 1984, Vol 36, Num 2, pp 379-387, issn 0011-393XArticle

Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestatROBISON, W. G. JR; KADOR, P. F; AKAGI, Y et al.Diabetes (New York, NY). 1986, Vol 35, Num 3, pp 295-299, issn 0012-1797Article

Relationship between plasma propranolol concentrations and dose of long-acting propranolol (INDERAL^®LA)DVORNIK, D; KRAML, M; DUBUC, J et al.Current therapeutic research. 1983, Vol 34, Num 4, pp 595-605, issn 0011-393XArticle

The metabolic disposition of acifram, a new antihyperlipidemic agent, in rats and dogsCAYEN, M. N; GONZALEZ, R; FERDINANDI, E. S et al.Xenobiotica (London. Print). 1986, Vol 16, Num 3, pp 251-263, issn 0049-8254Article

N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (tolrestat), a potent, orally active aldose reductase inhibitorSESTANJ, K; BELLINI, F; FUNG, S et al.Journal of medicinal chemistry (Print). 1984, Vol 27, Num 3, pp 255-256, issn 0022-2623Article

Dynamics of propranolol dosing schedulesCOELHO, J. B; DVORNIK, D; MULLANE, J. F et al.Clinical pharmacology and therapeutics. 1983, Vol 34, Num 4, pp 440-447, issn 0009-9236Article